Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
0.00%
)
Bitcoin
70,310.41
(
-0.29%
)
News Focus
News Focus
Post# of 257268
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: JohnWayne post# 204556

Wednesday, 06/14/2017 10:48:19 AM

Wednesday, June 14, 2017 10:48:19 AM

Post# of 257268
B-I reports phase-3 data for Humira FoB:

https://www.businesswire.com/news/home/20170614005617/en

As with other Humira FoBs, patent litigation will determine when these products can enter the US market. ABBV’s suit against AMGN (the first company to get FDA approval for a Humira FoB) involves 61 patents and has a trial date of Nov 2019.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today